Cellosaurus logo
expasy logo

Cellosaurus SUM1315MO2 (CVCL_5589)

[Text version]
Cell line name SUM1315MO2
Synonyms SUM1315M02; SUM1315-MO2; SUM-1315M02; SUM 1315M02; SUM-1315; SUM 1315; SUM1315; 1315M02
Accession CVCL_5589
Resource Identification Initiative To cite this cell line use: SUM1315MO2 (RRID:CVCL_5589)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: JWGray breast cancer cell line panel.
Part of: KuDOS 95 cell line panel.
Characteristics: Established from tumor tissue after two passages in nude mice.
Characteristics: EGF dependent.
Doubling time: 94.59 hours (JWGray panel).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
Sequence variations
HLA typing Source: PubMed=25960936
Class I
HLA-AA*31:01,32:01
HLA-BB*39:01,40:01
HLA-CC*03:04,12:03
Class II
HLA-DQDQA1*01:02,05:02
DQB1*03:02,06:04
HLA-DRDRB1*15:01,04

Source: PubMed=26589293
Class I
HLA-AA*31:01,32:01
HLA-BB*39:01,40:01
HLA-CC*03:04,12:03
Disease Invasive breast carcinoma of no special type (NCIt: C4194)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): DepMap=ACH-001389; PubMed=25877200

Markers:
AmelogeninX
CSF1PO12
D3S135818
D5S81813
D7S8208,12
D8S117913,15
D13S31711,12
D16S53911
D18S5112
D21S1128,29
FGA25
Penta D13,15
Penta E5
TH019.3
TPOX8,10
vWA17

Run an STR similarity search on this cell line
Web pages https://bioivt.com/sum-breast-cancer-cell-lines/
https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
Publications

PubMed=10424408; DOI=10.1023/A:1006135331912
Ignatoski K.M.W., Ethier S.P.
Constitutive activation of pp125fak in newly isolated human breast cancer cell lines.
Breast Cancer Res. Treat. 54:173-182(1999)

PubMed=10604729; DOI=10.1038/sj.bjc.6695007; PMCID=PMC2362964
Forozan F., Veldman R., Ammerman C.A., Parsa N.Z., Kallioniemi A.H., Kallioniemi O.-P., Ethier S.P.
Molecular cytogenetic analysis of 11 new breast cancer cell lines.
Br. J. Cancer 81:1328-1334(1999)

PubMed=10969801
Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Cancer Res. 60:4519-4525(2000)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=16541312; DOI=10.1007/s10549-006-9186-z
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Breast Cancer Res. Treat. 99:97-101(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008; PMCID=PMC2730521
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=19593635; DOI=10.1007/s10549-009-0460-8
Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Breast Cancer Res. Treat. 121:53-64(2010)

PubMed=21778573; DOI=10.3233/BD-2010-0307; PMCID=PMC3532890
Chavez K.J., Garimella S.V., Lipkowitz S.
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Breast Dis. 32:35-48(2010)

PubMed=22032724; DOI=10.1186/1755-8794-4-75; PMCID=PMC3227591
Ha K.C.H., Lalonde E., Li L.-L., Cavallone L., Natrajan R., Lambros M.B., Mitsopoulos C., Hakas J., Kozarewa I., Fenwick K., Lord C.J., Ashworth A., Vincent-Salomon A., Basik M., Reis-Filho J.S., Majewski J., Foulkes W.D.
Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.
BMC Med. Genomics 4:75.1-75.13(2011)

PubMed=23151021; DOI=10.1186/1471-2164-13-619; PMCID=PMC3546428
Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A.
Molecular characterisation of cell line models for triple-negative breast cancers.
BMC Genomics 13:619.1-619.14(2012)

PubMed=23401782; DOI=10.1155/2013/872743; PMCID=PMC3562669
Barnabas N., Cohen D.
Phenotypic and molecular characterization of MCF10DCIS and SUM breast cancer cell lines.
Int. J. Breast Cancer 2013:872743.1-872743.16(2013)

PubMed=23601657; DOI=10.1186/bcr3415; PMCID=PMC3672661
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33.1-R33.17(2013)

PubMed=24162158; DOI=10.1007/s10549-013-2743-3; PMCID=PMC3832776
Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M., Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Breast Cancer Res. Treat. 142:237-255(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110; PMCID=PMC3937590
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=32715085; DOI=10.1038/s41523-020-0173-z; PMCID=PMC7374090
Ethier S.P., Guest S.T., Garrett-Mayer E., Armeson K., Wilson R.C., Duchinski K., Couch D., Gray J.W., Kappler C.S.
Development and implementation of the SUM breast cancer cell line functional genomics knowledge base.
NPJ Breast Cancer 6:30.1-30.14(2020)

Cross-references
Cell line databases/resources CLO; CLO_0009916
cancercelllines; CVCL_5589
Cell_Model_Passport; SIDM01836
DepMap; ACH-001389
LINCS_HMS; 51081
LINCS_LDP; LCL-2066
SLKBase; 1106
Anatomy/cell type resources BTO; BTO:0005933
Biological sample resources BioSample; SAMN03471829
Chemistry resources PharmacoDB; SUM1315M02_1508_2019
Encyclopedic resources Wikidata; Q54970827
Experimental variables resources EFO; EFO_0001239
EFO; EFO_0022374
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-TABM-157
GEO; GSM217599
GEO; GSM421893
GEO; GSM1008915
GEO; GSM1053733
GEO; GSM1172896
GEO; GSM1172991
GEO; GSM1214566
GEO; GSM1374910
Polymorphism and mutation databases Cosmic; 904394
Cosmic; 997924
Cosmic; 1046961
Cosmic; 1287925
Cosmic; 1289417
Cosmic; 1460228
IARC_TP53; 24341
Progenetix; CVCL_5589
Sequence databases EGA; EGAS00001000610
Entry history
Entry creation04-Apr-2012
Last entry update10-Sep-2024
Version number34